864 results on '"Orlowski, Robert"'
Search Results
2. Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma over Three Decades
3. A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis.
4. The effect of care team-patient relationship on decision-making in relapsed/refractory multiple myeloma.
5. Clonal evolution of hematopoietic stem cells after cancer chemotherapy
6. Health‐related quality of life in transplant‐eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient‐reported outcomes from GRIFFIN
7. Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden
8. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation
9. MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis
10. Impact of Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) on AL Amyloidosis Outcomes
11. Long-Term Responders after Upfront Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma
12. Lower PG-Free Mel (Evomela) Clearance and Higher Exposure Are Associated with Better Treatment Response in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
13. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
14. Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX
15. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience
16. Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146
17. Analysis of East Asia Subgroup in Study 309/KEYNOTE-775: Lenvatinib plus pembrolizumab versus treatment of physician’s choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer
18. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation
19. Management and Outcomes of Patients with Refractory Solitary Plasmacytoma after Treatment with Definitive Radiation Therapy
20. Clinical trial design change implementation for inclusive studies
21. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial
22. Targeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma
23. OA-36 SBCMA predicts progression and is a biomarker of response in myeloma precursor disease followed on prospective studies
24. MM-360 Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relapsed/refractory Multiple Myeloma (RRMM): Results From the Dose-Expansion Phase of the CC-92480-MM-001 Trial
25. NSO-02 Characteristics of multiple myeloma patients with central nervous system involvement
26. POSTER: MM-360 Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results From the Dose-Expansion Phase of the CC-92480-MM-001 Trial
27. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma
28. POSTER: MM-372 A Phase III, Two-Stage, Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
29. P-164 Reduction in disease symptoms/impacts after daratumumab, lenalidomide, bortezomib, and dexamethasone treatment for transplant-eligible patients with newly diagnosed multiple myeloma (GRIFFIN study)
30. MM-372 A Phase III, Two-Stage, Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
31. P-399 Isatuximab promotes immune activation in the bone marrow microenvironment of patients with high risk smoldering multiple myeloma
32. Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma
33. P1330: CYTOREDUCTIVE CHEMOTHERAPY COULD ACCELERATE THE LOSS OF CLONAL DIVERSITY IN HEMATOPOIETIC STEM CELLS AND PROMOTES THE CONVERGENT EVOLUTION OF THERAPY-RELATED CLONAL HEMATOPOIESIS
34. P1299: OUTCOMES OF YOUNG ADULTS (AGED ≤40 YEARS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UPFRONT AUTOLOGOUS STEM CELL TRANSPLANT
35. PB2144: TRIAL IN PROGRESS: A PHASE 1/2 WINDOW OF OPPORTUNITY STUDY OF THE BCMAXCD3 BISPECIFIC ANTIBODY LINVOSELTAMAB IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA
36. P1279: OUTCOMES OF AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA WITH TWO OR MORE HIGH-RISK CYTOGENETIC ABNORMALITIES
37. P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 TRIAL
38. P1303: DARATUMUMAB-BASED MAINTENANCE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AFTER SALVAGE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
39. Single‐agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience
40. Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
41. Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies
42. Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis
43. Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma
44. TABLE 3 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
45. Supplementary Figure 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
46. Supplementary Figure 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
47. FIGURE 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
48. TABLE 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
49. TABLE 4 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
50. TABLE 5 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.